Annual report pursuant to Section 13 and 15(d)

Research, Development and License Agreement - Additional Information (Detail)

v3.20.4
Research, Development and License Agreement - Additional Information (Detail) - Bayer License Agreement
1 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
License, Collaboration and Manufacturing Agreements [Line Items]    
Upfront cash payment received $ 45,000,000.0  
Additional upfront reimbursement payment for research and process development 15,000,000.0  
Additional upfront cash payment entitle to receive for translational activities, invoiced amount $ 1,300,000 $ 1,300,000
Royalty eligible to receive term after first commercial sale 12 years  
Determined upfront payment for license in order to evaluate transaction price $ 45,000,000.0  
Determined research and process development activities in order to evaluate transaction price 15,000,000.0  
Determined additional specified translational activities in order to evaluate transaction price 5,000,000.0  
Revenue   0
Deferred revenue 61,300,000 61,300,000
Development or sales-based milestone payments received   0
Current Liabilities    
License, Collaboration and Manufacturing Agreements [Line Items]    
Deferred revenue 33,500,000 33,500,000
Long-Term Liabilities    
License, Collaboration and Manufacturing Agreements [Line Items]    
Deferred revenue 27,800,000 27,800,000
Maximum    
License, Collaboration and Manufacturing Agreements [Line Items]    
Additional upfront cash payment entitle to receive for translational activities 5,000,000.0 5,000,000.0
Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones $ 610,000,000.0 $ 610,000,000.0